These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 32218809)

  • 41. Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment.
    Li L; Yu R; Cai T; Chen Z; Lan M; Zou T; Wang B; Wang Q; Zhao Y; Cai Y
    Int Immunopharmacol; 2020 Nov; 88():106939. PubMed ID: 33182039
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.
    Black M; Barsoum IB; Truesdell P; Cotechini T; Macdonald-Goodfellow SK; Petroff M; Siemens DR; Koti M; Craig AW; Graham CH
    Oncotarget; 2016 Mar; 7(9):10557-67. PubMed ID: 26859684
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1.
    Roux C; Jafari SM; Shinde R; Duncan G; Cescon DW; Silvester J; Chu MF; Hodgson K; Berger T; Wakeham A; Palomero L; Garcia-Valero M; Pujana MA; Mak TW; McGaha TL; Cappello P; Gorrini C
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4326-4335. PubMed ID: 30770442
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of hypoxia-inducible factor 1 in tumor immune evasion.
    You L; Wu W; Wang X; Fang L; Adam V; Nepovimova E; Wu Q; Kuca K
    Med Res Rev; 2021 May; 41(3):1622-1643. PubMed ID: 33305856
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells.
    Yang M; Liu P; Wang K; Glorieux C; Hu Y; Wen S; Jiang W; Huang P
    Mol Oncol; 2017 Apr; 11(4):358-372. PubMed ID: 28218497
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB.
    Karyampudi L; Lamichhane P; Krempski J; Kalli KR; Behrens MD; Vargas DM; Hartmann LC; Janco JM; Dong H; Hedin KE; Dietz AB; Goode EL; Knutson KL
    Cancer Res; 2016 Jan; 76(2):239-50. PubMed ID: 26567141
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Major Role of NF-κB in the Depth of Invasion on Acral Melanoma by Decreasing CD8
    Usman HA; Hernowo BS; Tobing MDL; Hindritiani R
    J Pathol Transl Med; 2018 May; 52(3):164-170. PubMed ID: 29673240
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.
    Bouillez A; Rajabi H; Jin C; Samur M; Tagde A; Alam M; Hiraki M; Maeda T; Hu X; Adeegbe D; Kharbanda S; Wong KK; Kufe D
    Oncogene; 2017 Jul; 36(28):4037-4046. PubMed ID: 28288138
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade.
    Bai J; Gao Z; Li X; Dong L; Han W; Nie J
    Oncotarget; 2017 Dec; 8(66):110693-110707. PubMed ID: 29299180
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PD-1/PD-L1 pathway: current researches in cancer.
    Han Y; Liu D; Li L
    Am J Cancer Res; 2020; 10(3):727-742. PubMed ID: 32266087
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Al-Dughaishi M; Shalaby A; Al-Ribkhi K; Boudaka A; Boulassel MR; Saleh J
    Sultan Qaboos Univ Med J; 2019 Nov; 19(4):e277-e283. PubMed ID: 31897310
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer.
    Liu X; Yang Z; Latchoumanin O; Qiao L
    Therap Adv Gastroenterol; 2016 Nov; 9(6):853-860. PubMed ID: 27803740
    [TBL] [Abstract][Full Text] [Related]  

  • 53. STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC.
    Bu LL; Yu GT; Wu L; Mao L; Deng WW; Liu JF; Kulkarni AB; Zhang WF; Zhang L; Sun ZJ
    J Dent Res; 2017 Aug; 96(9):1027-1034. PubMed ID: 28605599
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypoxia-induced SOCS3 is limiting STAT3 phosphorylation and NF-κB activation in congenital heart disease.
    Gu Q; Kong Y; Yu ZB; Bai L; Xiao YB
    Biochimie; 2011 May; 93(5):909-20. PubMed ID: 21354254
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting hypoxia at the forefront of anticancer immune responses.
    Noman MZ; Chouaib S
    Oncoimmunology; 2014 Dec; 3(12):e954463. PubMed ID: 25964858
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
    Jiang Y; Zhan H
    Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Role of PD-1/PD-L1 in microenvironment of breast cancer].
    Ji P; Gong Y; Hu X
    Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):401-405. PubMed ID: 31216823
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.
    Noguchi T; Ward JP; Gubin MM; Arthur CD; Lee SH; Hundal J; Selby MJ; Graziano RF; Mardis ER; Korman AJ; Schreiber RD
    Cancer Immunol Res; 2017 Feb; 5(2):106-117. PubMed ID: 28073774
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanisms Of Hypoxia-Induced Immune Escape In Cancer And Their Regulation By Nitric Oxide.
    Graham C; Barsoum I; Kim J; Black M; Siemens RD
    Redox Biol; 2015 Aug; 5():417. PubMed ID: 28162279
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition.
    Cretella D; Digiacomo G; Giovannetti E; Cavazzoni A
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31500143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.